385 related articles for article (PubMed ID: 26225991)
1. CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape.
Hütter G; Bodor J; Ledger S; Boyd M; Millington M; Tsie M; Symonds G
Viruses; 2015 Jul; 7(8):4186-203. PubMed ID: 26225991
[TBL] [Abstract][Full Text] [Related]
2. CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.
Allers K; Schneider T
Curr Opin Virol; 2015 Oct; 14():24-9. PubMed ID: 26143158
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice.
Hofer U; Henley JE; Exline CM; Mulhern O; Lopez E; Cannon PM
J Infect Dis; 2013 Nov; 208 Suppl 2(Suppl 2):S160-4. PubMed ID: 24151324
[TBL] [Abstract][Full Text] [Related]
4. Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.
Myburgh R; Ivic S; Pepper MS; Gers-Huber G; Li D; Audigé A; Rochat MA; Jaquet V; Regenass S; Manz MG; Salmon P; Krause KH; Speck RF
J Virol; 2015 Jul; 89(13):6761-72. PubMed ID: 25903342
[TBL] [Abstract][Full Text] [Related]
5. Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.
Symonds G; Bartlett JS; Kiem HP; Tsie M; Breton L
AIDS Patient Care STDS; 2016 Dec; 30(12):545-550. PubMed ID: 27905841
[TBL] [Abstract][Full Text] [Related]
6. CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.
Duarte RF; Salgado M; Sánchez-Ortega I; Arnan M; Canals C; Domingo-Domenech E; Fernández-de-Sevilla A; González-Barca E; Morón-López S; Nogues N; Patiño B; Puertas MC; Clotet B; Petz LD; Querol S; Martinez-Picado J
Lancet HIV; 2015 Jun; 2(6):e236-42. PubMed ID: 26423196
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
[TBL] [Abstract][Full Text] [Related]
8. CCR5 as a natural and modulated target for inhibition of HIV.
Burke BP; Boyd MP; Impey H; Breton LR; Bartlett JS; Symonds GP; Hütter G
Viruses; 2013 Dec; 6(1):54-68. PubMed ID: 24381033
[TBL] [Abstract][Full Text] [Related]
9. The CRISPR-Cas9 induced CCR5 Δ32 mutation as a potent gene therapy methodology for resistance to HIV-1 variant: a review.
Saifullah M; Laghzaoui O; Ozyahyalar H; Irfan A
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2430-2463. PubMed ID: 38567606
[TBL] [Abstract][Full Text] [Related]
10. Designer Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV.
Almeida MJ; Matos A
Curr HIV Res; 2019; 17(5):306-323. PubMed ID: 31652113
[TBL] [Abstract][Full Text] [Related]
11. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
Cell Biosci; 2017; 7():47. PubMed ID: 28904745
[TBL] [Abstract][Full Text] [Related]
12. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
13. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
[TBL] [Abstract][Full Text] [Related]
14. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
[TBL] [Abstract][Full Text] [Related]
15. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.
Holt N; Wang J; Kim K; Friedman G; Wang X; Taupin V; Crooks GM; Kohn DB; Gregory PD; Holmes MC; Cannon PM
Nat Biotechnol; 2010 Aug; 28(8):839-47. PubMed ID: 20601939
[TBL] [Abstract][Full Text] [Related]
16. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.
Li L; Krymskaya L; Wang J; Henley J; Rao A; Cao LF; Tran CA; Torres-Coronado M; Gardner A; Gonzalez N; Kim K; Liu PQ; Hofer U; Lopez E; Gregory PD; Liu Q; Holmes MC; Cannon PM; Zaia JA; DiGiusto DL
Mol Ther; 2013 Jun; 21(6):1259-69. PubMed ID: 23587921
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.
Swamy MN; Wu H; Shankar P
Adv Drug Deliv Rev; 2016 Aug; 103():174-186. PubMed ID: 27013255
[TBL] [Abstract][Full Text] [Related]
18. [HIV: vision of a cure].
Boffi el Amari E
Rev Med Suisse; 2011 Oct; 7(312):1968, 1970-3. PubMed ID: 22097447
[TBL] [Abstract][Full Text] [Related]
19. Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.
Henrich TJ; Hanhauser E; Hu Z; Stellbrink HJ; Noah C; Martin JN; Deeks SG; Kuritzkes DR; Pereyra F
AIDS; 2015 May; 29(8):867-76. PubMed ID: 25730507
[TBL] [Abstract][Full Text] [Related]
20. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.
Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R
Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
